跳至主要内容
临床试验/NCT01689792
NCT01689792已完成4 期

A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)

Norgine1 个研究点 分布在 1 个国家目标入组 398 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Norgine
入组人数
398
试验地点
1
主要终点
Polyp detection rate

研究概览

简要总结

To compare the polyp and adenoma detection rate of MOVIPREP versus an oral Sodium Picosulfate/Magnesium Citrate solution.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Screening
盲法
Single (Investigator)

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient's written informed consent must be obtained prior to inclusion.
  • •Male or female outpatients or inpatients aged 40 to 80 years with an indication for complete colonoscopy.
  • •Willing to undergo a colonoscopy for diagnostic or surveillance purposes
  • •Patients with a known personal of familial risk of colon neoplasia, willing to undergo a screening colonoscopy
  • •Willing, able and competent to complete the entire procedure and to comply with study instructions.
  • •Females of childbearing potential must employ an adequate method of contraception.

排除标准

  • •History of gastric emptying disorders.
  • •History of ileus, toxic megacolon, gastrointestinal obstruction and colonic perforation.
  • •History of phenylketonuria.
  • •Known glucose-6-phosphate dehydrogenase deficiency.
  • •Known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/sodium ascorbate.
  • •History of colonic resection.
  • •Requirement for permanent medication and associated stable serum concentrations (e.g. neuroleptic drugs).
  • •Presence of congestive heart failure (NYHA III + IV).
  • •Acute life-threatening cardiovascular disease.
  • •Documented history of severe renal insufficiency (creatinine clearance <30 ml/min).
  • •Other contraindication described in the summary of product characteristics (SmPC) of either preparation.
  • •Patient has a condition, clinically significant laboratory results, or is in a situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly.
  • •Application of any unlicensed medication within the previous 3 months or participation in any other research study in the last 3 months.
  • •Females who are pregnant, nursing or planning a pregnancy.
  • •Patients who, in the opinion of the investigator, may not be compliant with the study requirements.
  • •Previous participation in this clinical study.

研究组 & 干预措施

CitraFleet

Active Comparator

Administration of CitraFleet

干预措施: CitraFleet (Drug)

MOVIPREP

Experimental

Administration of MOVIPREP

干预措施: MOVIPREP (Drug)

结局指标

主要结局

Polyp detection rate

时间窗: At colonoscopy

Polyp detection rate defined as number of patients with at least one polyp or flat lesion as recorded by the endoscopist

次要结局

  • Adenoma Detection Rate (ADR)(At the Colonoscopy)
  • ADR and PDR by location(at the colonoscopy)
  • Cancer detection rate(at the colonoscopy)
  • Flat lesion only detection rate(at the colonoscopy)
  • Advanced risk lesion detection rate(at the colonoscopy)
  • Colonoscopy completion rate(at the colonoscopy)
  • Colon cleansing quality(at the colonoscopy)
  • Acceptability and tolerability of medication using patient questionnaires(Throughout the study)

研究者

发起方
Norgine
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验